Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Amikacin

Amikacin: A Comprehensive Guide to a Potent Aminoglycoside Antibiotic

Introductions

In the battle against severe bacterial infections, few antibiotics have the power and versatility of Amikacin. As a broad-spectrum aminoglycoside, Amikacin stands out for its effectiveness against multi-drug-resistant (MDR) organisms, especially in critical care and hospital-acquired infections. Discovered in the 1970s as a semisynthetic derivative of kanamycin A, Amikacin is valued for its robust antibacterial profile, chemical stability, and relative resistance to bacterial inactivation enzymes, making it a go-to option in modern infectious disease management.

Pharmacological Overview:

Chemical Profile

  • IUPAC Name: (2S)-4-amino-2-hydroxybutanoic acid, glycosidically linked to multiple deoxystreptamine residues

  • Molecular Formula: C22H43N5O13

  • Molecular Weight: 585.6 g/mol

  • Drug Class: Aminoglycoside antibiotic

Formulations

  • Injection: 250 mg/mL, 500 mg/mL, 1 g/4 mL

  • Inhalation (off-label use): Nebulized solutions for cystic fibrosis or resistant lung infections

  • Intrathecal/Intraventricular: In severe CNS infections (off-label, specialist use)

Mechanism of Action:

Amikacin acts by irreversibly binding to the 30S ribosomal subunit of bacterial cells, disrupting the initiation of protein synthesis and causing the incorporation of incorrect amino acids. This leads to dysfunctional proteins and bacterial cell death, making it bactericidal rather than bacteriostatic.

It is concentration-dependent, meaning higher peak levels correspond with increased bacterial kill rates, an important aspect for dosing regimens.

Spectrum of Activity:

Amikacin is active against a wide range of Gram-negative aerobes, with limited Gram-positive activity. It is particularly effective against:

Gram-Negative Bacteria

  • Pseudomonas aeruginosa

  • Escherichia coli

  • Klebsiella pneumoniae

  • Proteus spp.

  • Enterobacter spp.

  • Acinetobacter baumannii (including MDR strains)

Gram-Positive Bacteria

  • Staphylococcus aureus (especially MRSA when used in combination)

  • Mycobacterium tuberculosis and Mycobacterium avium complex (MAC)

Note: Anaerobes and many streptococci are generally resistant due to oxygen-dependent uptake mechanisms required for aminoglycosides.

Clinical Indications:

Amikacin is generally reserved for severe infections or when resistance to other antibiotics is suspected or proven. Common clinical uses include:

1. Hospital-Acquired Pneumonia (HAP) & Ventilator-Associated Pneumonia (VAP)

  • Often part of combination therapy with beta-lactams or carbapenems for Pseudomonas or Acinetobacter coverage.

2. Urinary Tract Infections (UTIs)

  • Effective in complicated UTIs and pyelonephritis, especially when caused by MDR Enterobacteriaceae.

3. Bacteremia and Sepsis

  • Used empirically in neutropenic fever or septic shock until sensitivities are known.

4. Intra-abdominal Infections

  • In combination regimens to cover Gram-negative rods, especially in ICU patients.

5. Tuberculosis (Second-Line)

  • Used in drug-resistant TB when first-line treatments fail.

6. Cystic Fibrosis (Inhaled Form)

  • Nebulized Amikacin may be used off-label for chronic Pseudomonas colonization.

Pharmacokinetics:

Parameter Value
Absorption Poor orally, hence parenteral use
Distribution Extracellular fluid, low CNS penetration
Half-life ~2-3 hours (longer in renal impairment)
Excretion Renal (unchanged), >90% excreted in urine
Volume of Distribution (Vd) ~0.2–0.3 L/kg

Because of its renal clearance, dose adjustment is mandatory in patients with impaired kidney function.

Dosing Guidelines:

Amikacin is typically dosed based on actual body weight, renal function, and infection severity.

Traditional Dosing

  • 15 mg/kg/day divided every 8 or 12 hours

  • Adjusted per renal function and peak/trough levels

Extended Interval Dosing (Once-daily)

  • 15–20 mg/kg IV once daily

  • Safer and more convenient in many clinical settings

  • Avoid in pregnancy, burns, ascites, or endocarditis

Therapeutic Drug Monitoring (TDM)

  • Peak level goal: 20–30 mcg/mL (efficacy)

  • Trough level goal: <5 mcg/mL (toxicity risk)

Side Effects and Toxicity:

Amikacin is a nephrotoxic and ototoxic agent, and its use requires careful monitoring.

Common Side Effects

  • Nausea, headache, fever, injection site reactions

Serious Toxicities

Type Description
Nephrotoxicity Reversible, dose-dependent; monitor creatinine and adjust dose
Ototoxicity Irreversible; affects both vestibular and auditory function
Neurotoxicity Rare; can cause peripheral neuropathy, neuromuscular blockade

Risk factors for toxicity include older age, concurrent nephrotoxic drugs, dehydration, prolonged therapy, and high trough levels.

Contraindications and Cautions:

Contraindications

  • Hypersensitivity to aminoglycosides

  • History of aminoglycoside-induced ototoxicity or nephrotoxicity

Use With Caution In

  • Renal impairment

  • Myasthenia gravis (neuromuscular blockade)

  • Pregnancy (Category D – potential fetal toxicity)

Drug Interactions:

  • Other nephrotoxic drugs: Vancomycin, loop diuretics, amphotericin B

  • Neuromuscular blockers: Additive effect may lead to respiratory depression

  • Cisplatin: Enhanced ototoxicity

Avoid concurrent use where possible or ensure enhanced monitoring.

Resistance Patterns:

Amikacin is less susceptible to inactivation by aminoglycoside-modifying enzymes (AMEs), which is why it often retains activity against organisms resistant to gentamicin or tobramycin.

However, resistance can occur due to:

  • Efflux pumps

  • Ribosomal mutations

  • Enzymatic inactivation (e.g., AAC, ANT, APH enzymes)

  • Biofilm formation (especially in Pseudomonas)

Routine susceptibility testing is essential before prolonged use.

Amikacin vs. Other Aminoglycosides:

Drug Spectrum Stability Resistance Usage
Amikacin Broadest Gram-negative High Least susceptible MDR infections
Gentamicin Moderate Moderate More susceptible UTI, synergy
Tobramycin Best for Pseudomonas Moderate Moderate CF, pneumonia
Streptomycin TB-specific Low Common 2nd-line TB

Amikacin is often the last-line aminoglycoside in resistant Gram-negative infections due to its broad spectrum and low resistance rate.

Role in Antimicrobial Stewardship:

Due to its toxicity, Amikacin should be:

  • Reserved for documented or suspected resistant infections

  • Used in short courses with regular monitoring

  • Reassessed within 48–72 hours based on culture data

De-escalation is critical

Once susceptibilities are known, consider switching to a safer, narrower-spectrum agent.

Emerging Formulations and Innovations:

Liposomal Amikacin (Arikayce)

  • FDA-approved for Mycobacterium avium complex (MAC) lung disease

  • Inhaled formulation for direct lung delivery

  • Reduces systemic toxicity

Nanoformulations

  • Under investigation for targeted delivery

  • May offer reduced toxicity and improved efficacy

Case Study Example:

A 65-year-old ICU patient with ventilator-associated pneumonia due to MDR Pseudomonas is started on meropenem + Amikacin. Serum creatinine is monitored daily. Trough levels remain <5 mcg/mL, and the infection resolves by Day 7. The patient is de-escalated to oral ciprofloxacin based on culture sensitivity. No renal or auditory toxicity occurs.

Conclusion:

Amikacin remains a powerful and reliable antibiotic, especially in the face of multi-drug resistant Gram-negative infections. With judicious use, therapeutic monitoring, and proper stewardship, it serves as a critical option in modern infectious disease management. Its efficacy, stability against resistance mechanisms, and versatility across infections make it indispensable in the antimicrobial arsenal—especially in hospitals and ICUs. However, its potential for nephrotoxicity and ototoxicity mandates careful patient selection, dosing, and monitoring. As antibiotic resistance continues to rise, Amikacin’s role will likely grow—supported by innovation in formulations and smarter drug delivery systems.

References:

  1. Goodman & Gilman's: The Pharmacological Basis of Therapeutics

  2. Clinical Infectious Diseases Journal – Aminoglycoside Toxicity

  3. Sanford Guide to Antimicrobial Therapy

  4. UpToDate: Aminoglycosides Overview

  5. FDA Prescribing Information – Amikacin Sulfate

  6. Arikayce (Liposomal Amikacin) Product Monograph.